Suppression of the TRIF-dependent signaling pathway of Toll-like receptor by CDr10b in RAW264.7 macrophages
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gu, Gyo-Jeong | - |
dc.contributor.author | Ahn, Sang-il | - |
dc.contributor.author | Kim, Ji-Soo | - |
dc.contributor.author | Hong, Chae-Yeon | - |
dc.contributor.author | Lee, Sung-Chan | - |
dc.contributor.author | Chang, Young-Tae | - |
dc.contributor.author | Choi, Tae Hyun | - |
dc.contributor.author | Kim, Byoung Soo | - |
dc.contributor.author | Youn, Hyung-Sun | - |
dc.date.accessioned | 2021-08-11T19:44:45Z | - |
dc.date.available | 2021-08-11T19:44:45Z | - |
dc.date.issued | 2015-09 | - |
dc.identifier.issn | 1567-5769 | - |
dc.identifier.issn | 1878-1705 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/10325 | - |
dc.description.abstract | Toll-like receptors (TLRs) recognize distinct pathogen-associated molecular patterns and play a critical role in innate immune responses. TLR signaling pathways can be largely classified as either myeloid differential factor 88 (MyD88)- or toll-interleukin-1 receptor domain-containing adapter inducing interferon-beta (TRIF)-dependent pathways. Compound of Designation red 10 binding (CDr10b) was synthesized to investigate its role in neuroinflammatory diseases. This study was conducted to determine whether CDr10b can affect TLR signaling pathways. CDr10b suppressed NF-kappa B activation as well as COX-2 and iNOS expression induced by TLR3 or TLR4 agonists. CDr10b also suppressed the activation of interferon regulatory factor 3 (IRF3) and the expression of interferon inducible protein-10 (IP-10) induced by TLR3 or TLR4 agonists. These results indicate that CDr10b can modulate the TRIF-dependent pathway of TLRs and has the potential to become a new therapeutic drug for chronic inflammatory diseases. (C) 2015 Elsevier B.V. All rights reserved. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Elsevier BV | - |
dc.title | Suppression of the TRIF-dependent signaling pathway of Toll-like receptor by CDr10b in RAW264.7 macrophages | - |
dc.type | Article | - |
dc.publisher.location | 네델란드 | - |
dc.identifier.doi | 10.1016/j.intimp.2015.05.017 | - |
dc.identifier.scopusid | 2-s2.0-84930627553 | - |
dc.identifier.wosid | 000361413500004 | - |
dc.identifier.bibliographicCitation | International Immunopharmacology, v.28, no.1, pp 29 - 33 | - |
dc.citation.title | International Immunopharmacology | - |
dc.citation.volume | 28 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 29 | - |
dc.citation.endPage | 33 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Immunology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Immunology | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | INTERFERON REGULATORY FACTOR-3 | - |
dc.subject.keywordPlus | PATTERN-RECOGNITION RECEPTORS | - |
dc.subject.keywordPlus | INNATE IMMUNITY | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | LIPOPOLYSACCHARIDE | - |
dc.subject.keywordPlus | CYCLOOXYGENASE-2 | - |
dc.subject.keywordPlus | TRANSCRIPTION | - |
dc.subject.keywordPlus | 6-SHOGAOL | - |
dc.subject.keywordPlus | KINASE | - |
dc.subject.keywordAuthor | CDr10b | - |
dc.subject.keywordAuthor | Toll-like receptor | - |
dc.subject.keywordAuthor | IRF3 | - |
dc.subject.keywordAuthor | IP-10 | - |
dc.subject.keywordAuthor | TRIF | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.